MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
6:40 AM | Friday | Nov 13, 2026 Business Wire

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

News Thumbnail
6:35 AM | Friday | Nov 13, 2026 Business Wire

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

News Thumbnail
12:12 PM | Thursday | Nov 12, 2026 MarketBeat

3 Pharmaceutical Stocks That Offer Safety and Growth

News Thumbnail
11:16 AM | Thursday | Nov 12, 2026 MarketBeat

What Merck KGaA (MRK) Said on Its Q3 Earnings Call

News Thumbnail
6:45 AM | Thursday | Nov 12, 2026 Business Wire

Merck to Participate in the Jefferies Global Healthcare Conference in London

News Thumbnail
9:56 AM | Wednesday | Nov 11, 2026 Benzinga

EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

News Thumbnail
1:14 PM | Tuesday | Nov 10, 2026 Business Wire

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

News Thumbnail
12:41 PM | Monday | Nov 9, 2026 Zacks Investment Research

INVA or MRK: Which Is the Better Value Stock Right Now?

News Thumbnail
9:51 AM | Monday | Nov 9, 2026 Zacks Investment Research

MRK's 2027 Outlook Challenging, Long-Term Prospects Promising

News Thumbnail
6:08 AM | Sunday | Nov 8, 2026 247 Wallst

Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap

News Thumbnail

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Business Wire

6:40 AM | Friday | Nov 13, 2026

news photo
Loading...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV dis.

Read full article redirect
6:40 AM | Friday | Nov 13, 2026

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV dis.

Read full article arrow
News Thumbnail
6:35 AM | Friday | Nov 13, 2026

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck's first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult p.

Read full article arrow
News Thumbnail
12:12 PM | Thursday | Nov 12, 2026

3 Pharmaceutical Stocks That Offer Safety and Growth

MarketBeat

Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven strong portfolio gains for active and passive investors.

Read full article arrow
News Thumbnail
11:16 AM | Thursday | Nov 12, 2026

What Merck KGaA (MRK) Said on Its Q3 Earnings Call

MarketBeat

Merck KGaA ETR: MRK raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare portfolio.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Nov 12, 2026

Merck to Participate in the Jefferies Global Healthcare Conference in London

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference in London.

Read full article arrow
News Thumbnail
9:56 AM | Wednesday | Nov 11, 2026

EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

Benzinga

The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposure and Merck & Co‘s (NYSE:MRK) and Bristol-Myers Squibb Co‘s (NYSE:BMY) confronting a potentially bigger test in the years ahead.

Read full article arrow
News Thumbnail
1:14 PM | Tuesday | Nov 10, 2026

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

Business Wire

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult tre.

Read full article arrow
News Thumbnail
12:41 PM | Monday | Nov 9, 2026

INVA or MRK: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now?

Read full article arrow
News Thumbnail
9:51 AM | Monday | Nov 9, 2026

MRK's 2027 Outlook Challenging, Long-Term Prospects Promising

Zacks Investment Research

Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential.

Read full article arrow
News Thumbnail
6:08 AM | Sunday | Nov 8, 2026

Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap

247 Wallst

Two men start the same one-minute cancer shot on the same day, yet their Medicare bills will diverge sharply. A hidden enrollment deadline, likely missed years ago, may decide who pays and who doesn't.

Read full article arrow
News Thumbnail